Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077917 · ClinicalTrials.gov registry record · Phase 3
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
A Phase 3 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT05077917 is a Phase 3 study that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 22 participants.
The verdict
NCT05077917, a Phase 3 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life. Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn will be administered as a nebulized treatment four times a day for four days followed by intranasal administration for two weeks. Investigators may also screen for biomarkers that could indicate inflammatory responses and treatment-induced improvement. Participants will receive either study drug or placebo which will be administered by nebulization for 4 days followed by 14 days of intranasal administration. Participants will be followed while in the hospital and then as outpatients up to day 21 following randomization.
Interventions
- OTHER Placebo
- DRUG Cromolyn Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05077917
The ClinicalTrials.gov registry entry for NCT05077917 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05077917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05077917 about?
NCT05077917 is a clinical study titled "Cromolyn Sodium for Treatment of COVID-19 Pneumonia". The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life. Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pn...
What is the current status of trial NCT05077917?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2021-11-15. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05077917?
The interventions under investigation include: Placebo (OTHER), Cromolyn Sodium (DRUG).
Who is sponsoring clinical trial NCT05077917?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.